Épisodes

  • Targeting the Fire Within: How InflaRx Is Redefining Inflammation Control

    Targeting the Fire Within: How InflaRx Is Redefining Inflammation Control
    Nov 20 2025
    InflaRx CEO Dr. Niels Riedmann joins Rx for Biotech to discuss how the company is pioneering complement-directed therapies to control severe inflammation and autoimmune disease. We break down the science behind INF904, and why C5a is such a powerful immune driver, and how precision immunology is shaping the next wave of treatment innovation.
    Voir plus Voir moins
    35 min
  • How Novel Genetic Medicines may improve treatment of chronic Neurological Diseases

    How Novel Genetic Medicines may improve treatment of chronic Neurological Diseases
    Nov 11 2025
    In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery. EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.
    Voir plus Voir moins
    29 min
  • Restoring Breath: Biologic Innovation for the Most Vulenerable Patients

    Restoring Breath: Biologic Innovation for the Most Vulenerable Patients
    Oct 28 2025
    Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.
    Voir plus Voir moins
    21 min
  • Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy

    Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy
    Oct 14 2025
    In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.
    Voir plus Voir moins
    29 min
  • The Alpha Edge: Perspective Therapeutics on the Future of Theranostics and Radiopharmaceutical Therapies

    The Alpha Edge: Perspective Therapeutics on the Future of Theranostics and Radiopharmaceutical Therapies
    Sep 9 2025
    In this episode of Tc for Biotech, host Chris Leidli sits down with Thijs Spoor, CEO of Perspective Therapeutics, to unpack the future of radiopharmaceuticals for the treatment of cancer. This conversation goes beyond the science to explore the infrastructure and strategy that determines success in bringing target cancer therapies to patients.
    Voir plus Voir moins
    37 min
  • Harnessing the Immune System: PDS Biotech’s NextGen Approach to Cancer Treatment

    Harnessing the Immune System: PDS Biotech’s NextGen Approach to Cancer Treatment
    Aug 21 2025
    In this episode of Rx for Biotech, host Chris Leidli sits down with Dr. Frank Bedu-Addo, CEO of PDS Biotechnology, to discuss how the company is reimagining immunotherapy with its proprietary Versamune® T-cell activating platform.
    Voir plus Voir moins
    40 min
  • How Nonacus is Changing Cancer Detection with CEO, Jeff Bousfield

    How Nonacus is Changing Cancer Detection with CEO, Jeff Bousfield
    Aug 5 2025
    Early cancer detection doesn't have to mean invasive tests. In this podcast episode, we sit down with Jeff Bousfield, CEO of Nonacus Cancer Diagnostics, to explore how his UK-based company is revolutionizing precision cancer diagnostics with a powerful suite of non-invasive tools. Jeff shares the human story behind the science and why he believes the future of cancer care starts with precision diagnostics tools that are faster, less invasive, and more accessible to patients.
    Voir plus Voir moins
    27 min
  • Hope in Hard Places: A Potential New Option for Patients with Pancreatic Cancer

    Hope in Hard Places: A Potential New Option for Patients with Pancreatic Cancer
    Jul 24 2025
    Metastatic pancreatic cancer remains one of the deadliest cancers, but a new approach is taking shape - and it's showing promise in early clinical studies. In this episode, Dan Schmitt, President and CEO of Actuate Therapeutics, shares how elraglusib, an investigational targeted therapy, may provide a new option for patients with metastatic pancreatic cancer. We explore the urgent unmet need and why Dan thinks this could be a turning point for one of oncology's toughest challenges.
    Voir plus Voir moins
    43 min